Objective: This report summarizes influenza activity in Canada during the
Influenza in Canada, 2012-2013 season

Introduction
Influenza is a respiratory infection usually caused by influenza A or B viruses. In Canada, it generally occurs each year during the late fall and winter months. Influenza infection causes primary illness and can also lead to severe secondary medical complications, including viral pneumonia, secondary bacterial pneumonia and worsening of underlying medical conditions. It is estimated that in Canada, an average of 12,200 hospitalizations are related to influenza (1) (2) (3) and approximately 3,500 deaths are attributable to influenza annually (4) . National influenza surveillance is coordinated through the FluWatch program of the Centre for Immunization and Respiratory Infectious Diseases (CIRID) at the Public Health Agency of Canada. The primary objectives of this program are early detection and timely reporting of influenza activity in Canada and abroad as well as monitoring circulating strains of influenza virus such as antigenic characterization, identification of new subtypes and changes in antiviral resistance.
FluWatch collected data and information on influenza activity from a variety of sources and disseminated it weekly during the active influenza season (September to mid-May) and biweekly during the low season (mid-May to August). Information was available to health professionals and the public through e-mail and the FluWatch website www.phac-aspc.gc.ca/fluwatch/.
This report provides an epidemiologic and virologic summary of influenza activity in Canada during the 2012 -2013 season.
Methods
This report is based on the six primary indicators of influenza activity reported by the FluWatch program on a weekly basis across Canada and between August 26, 2012 (week 35) and August 24, 2013 (week 34): (I) sentinel laboratory-based influenza and other respiratory virus detections; (II) strain characterization and antiviral resistance for circulating influenza viruses; (III) primary care consultation rates of influenza-like illness (ILI) by sentinel practitioners; (IV) regional influenza activity levels; (V) influenza-associated hospitalizations and deaths; and (VI) pharmacy surveillance.
These data sets come from ongoing public health surveillance and are exempt from research ethics board approval.
Surveillance dataset (I) Sentinel laboratory-based influenza detections
Influenza detections were reported through the sentinel laboratory-based Respiratory Virus Detections Surveillance System (RVDSS) in aggregate and with case details. Participating laboratories reported the total number of tests performed for influenza and the total number of positive tests. Samples from the territories are tested by reference laboratories in nearby provinces and aggregated into provincial results. Samples with caselevel data were attributable to a territory and reported independently from the province testing the sample.
(II) Strain characterization and antiviral resistance for circulating influenza viruses
The NML conducted national surveillance on human influenza virus strains in collaboration with provincial laboratories and other Canadian hospital-and university-based laboratories. A subset of weekly influenza detections across Canada were referred to the NML for further testing to provide strain characterization and evaluation of antigenic changes, as well as antiviral resistance in the circulating influenza virus strains.
(III) Primary care consultation rates of ILI by sentinel practitioners CIRID recruited and managed the participation of sentinel physicians in seven provinces and three territories. In the remaining three provinces (British Columbia, Alberta and Saskatchewan), sentinel recruitment and reporting was managed by independent provincial programs. For one clinic day each week, sentinels reported the total number of patients seen for any reason (denominator) and the total number of patients meeting a standard national case definition for ILI (numerator).
(IV) Regional influenza activity levels and outbreaks Provinces and territories were subdivided into surveillance regions. Provincial and territorial epidemiologists assessed the weekly influenza activity level in their respective jurisdictions based on laboratory reports of influenza detections, presence of ILI and reports of outbreaks of influenza or ILI. There were four standard categories of activity: no activity, sporadic activity, localized activity and widespread activity. Outbreaks in hospitals and long-term care facilities (LTCF) were reported weekly, where an outbreak was defined as two or more cases of ILI within a seven-day period and included at least one laboratory-confirmed case of influenza. The pharmacy surveillance system is coordinated by the Centre for Foodborne, Environmental and Zoonotic Infectious Diseases (CFEZID) using data provided by participating pharmacies to RxCanada. In 2012 -13, approximately 2,500 stores from 15 major pharmacy chains contributed over-the-counter and prescription data. Participating pharmacies were present in all provinces and territories except Nunavut and 85% of health regions in Canada. Data was collected on new and refill prescription medications purchased, which are categorized as "antiviral" (including oseltamivir, zanamivir and amantadine) and "other" (all other prescriptions).
Results
Sentinel laboratory-based influenza and other respiratory virus detections
During the 2012 -13 season, sentinel laboratories tested 190,376 specimens for influenza and 31,737 (16.7%) were positive. Of the positive specimens, 27,020 (85.1%) were influenza A and 4,717 (14.9%) were influenza B. Among the seasonal influenza A viruses, 10,669 (39.5%) were subtyped and 9,395 (88.1%) were influenza A (H3N2) and 1,274 (11.9%) were influenza A (H1N1) pdm09 (Figure 1 ). Among the 26,546 cases for which information on age and type/subtype was received this season, adults ≥65 years of age comprised 41.1% of the influenza cases ( Table 1) . Approximately 45% of the influenza A cases occurred in adults ≥65 years of age and 45.9% of the influenza B cases occurred in children ≤19 years of age. Antigenic characterization and antiviral resistance The NML tested 1,508 influenza viruses for resistance to oseltamivir, 1,505 viruses for resistance to zanamivir and 1,344 influenza A viruses for resistance to amantadine. Of 653 A (H3N2) viruses tested, 1 (0.2%) was resistant to oseltamivir and zanamivir. Of 254 A (H1N1) viruses tested,one(0.4%) were resistant to oseltamivir and all were susceptible to zanamivir. Of 601 B viruses tested, three (0.5%) were resistant to oseltamivir and zanamivir. All but one A (H3N2) virus was resistant to amantadine.
Primary care consultation rates of influenza-like illness (ILI)
Of the 450 sentinels submitting at least one ILI report during the season, 97% reported during the active influenza season (October to May / weeks 40 to 20), with 46% reporting for at least 15 of the 33 weeks during the active period.
The peak ILI consultation rate was 67.7 per 1,000 patient visits and occurred during the week ending December 29, 2012 (week 52), similar to the peak percentage of laboratory tests positive for influenza (Figure 3) . The weekly ILI consultation rates exceeded the expected range, based on mean observations rates for the previous seasons since 1996 -97 (excluding rates from the pandemic period), in week 48 and between weeks 52 (2012) and week 5 (2013) . Weekly ILI consultations rates remained within or below the expected range for the rest of the season. 
Regional influenza activity levels and outbreaks
Provincial and territorial epidemiologists report the geographic distribution of influenza in their jurisdiction. The geographic distribution of influenza was most extensive during the week ending January 12, 2013 (week 2) with 14 regions reporting widespread activity and 26 regions reporting localized activity. The week ending June 15, 2013 (week 24) was the first week none of the regions reported widespread or localized influenza activity following the active influenza season. There were 53 hospital outbreaks and 676 LTCF outbreaks reported during the season, with the number of outbreaks peaking during the week ending January 12, 2013 (week 2).
Influenza-associated severe outcomes (hospitalizations and deaths)
During the 2012 -13 influenza season 5,110 influenza-associated hospitalizations were reported from eight provinces and territories. Cumulative reported rates (per 100,000 population) for hospitalizations by age groups were calculated based on the population of participating provinces and territories. The cumulative hospitalization rate for all age groups was 25.0 per 100,000. By age group, the hospitalization rates were 66.4 (0-4 years), 8.6 (5-19 years), 6.5 (20-44 years), 15.4 (45-64 years) and 94.1 (≥65 years). The cumulative death rate was 1.7 per 100,000.
In addition to provincial/territorial reports, Cases were also reported by two hospital surveillance networks. IMPACT reported 889 paediatric hospitalizations and PCIRN-SOS reported 1,812 adult hospitalizations. ICU admission was required for 13% of the paediatric hospitalizations and 12% of the adult hospitalizations (Figure 4) . Influenza A was the predominant strain identified in hospitalized cases. Of the 889 children hospitalized, 70% (n=624) were younger than five years of age and 47% (n=419) were healthy prior to infection. A total of 329 hospitalized children had underlying health conditions for which influenza immunization is recommended by the National Advisory Committee on Immunization (5). Only one paediatric death was reported.
Of the 1,812 adults hospitalized, 68% (n=1,230) were ≥65 years of age and 107 resulted in death. Of the 286 individuals who were admitted to ICU or died, 122 had underlying medical conditions, two had no underlying medical conditions and medical history was unknown for the remaining individuals.
Antiviral drugs -pharmacy surveillance
The overall Canadian antiviral prescription rate peaked in week 1 at 349 antiviral prescriptions per 100,000 new prescriptions dispensed. The antiviral prescription rate was highest in those ≥65 years of age and peaked at 750 prescriptions per 100,000 prescriptions dispensed and was lowest in infants (0-2 years of age) and peaked at 138 prescriptions per 100,000 prescriptions dispensed ( Figure 5 ). There are a number of limitations that need to be considered when interpreting results from the FluWatch surveillance program. Laboratory testing, surveillance and reporting protocols have varied prior to, during and post-pandemic and vary between provinces and territories. Therefore comparisons of laboratory findings (e.g. percentage of positive tests and number of positive laboratory-confirmed cases) over time as well as differences between jurisdictions need to be interpreted in light of these differences. Several factors affect the number of isolates sent to the NML such as limitations to culture isolates in provincial laboratories and samples of clinical interest. A greater proportion of the early isolates may also be analyzed to get a better understanding of the circulating strains for the coming season. Because only a subset of influenza viruses is characterized by the NML, the distribution of strain information is not representative of influenza detections reported by all laboratories contributing to RVDSS. Age-specific data for ILI consultation rates as well as laboratory testing for influenza may be affected by biases in health care utilization and physician testing behaviour. ILI consultation rates across time and between jurisdictions may vary with sentinel participation, differences in coverage rates as well as the cocirculation of other respiratory viruses. The true number of individuals affected by influenza in the population is not reflected in the data as FluWatch relies on sentinel data sources.
Duplicate reporting of hospitalizations and deaths is possible where a reporting jurisdiction has one or more hospitals participating in IMPACT or PCIRN-SOS. The reason for hospitalization or cause of death reported by provinces and territories does not have to be attributable to influenza for reporting purposes. Not all provinces/territories report aggregate hospitalizations or deaths, which makes these data incomplete at the national level.
There are a number of limitations associated with the data sources used in the FluWatch program, however, these data sources collectively inform influenza epidemiology in Canada over the season and allow for comparison between seasons. The FluWatch program continues to strengthen influenza surveillance in Canada in collaboration with national and international surveillance partners.
